Summary
Quantification of fibrinopeptides release is widely used to investigate fibrinogen
activation, and standard chromatographic or capillary electrophoretic procedures are
readily available. However, in the analyses of fibrinopeptide mixtures derived from
the action of thrombin on human fibrinogen, a few unidentified peaks are usually present.
The composition of these peaks was studied by reverse-phase HPLC/MS, revealing a single
major anomalous peptide having a molecular mass of 1384.4. A further MS/MS analysis
allowed the identification of this form, as a Nterminally truncated fibrinopeptideB
(fpB) lacking the first two residues (pyroglutamic acid and glycine). This previously
unidentified, relatively low-abundance form (∼7%) has been found consistently in our
fibrinopeptides preparations, and analysis of the parent Bβ-chain suggest that it
is likely present in circulating fibrinogen. In addition, deamidated forms of all
fpB species (including desArgB), resulting from the conversion of asparagine to aspartic
acid, were also identified. Overall, these previously unreported forms constitute
a substantial amount of fpB (up to ∼17% of the total), and should be taken into account
for a reliable quantitative analysis of fpB release.
Keywords
Blood coagulation - human - fibrinogen - fibrinopeptides - chromatography - mass spectrometry